Cassava Sciences to Present at H.C. Wainwright’s 22nd Annual Global Investment Conference
Cassava Sciences, a clinical-stage biotech company focused on Alzheimer’s disease, will present a corporate overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cassava Sciences, a clinical-stage biotech company focused on Alzheimer’s disease, will present a corporate overview at the H.C. Wainwright’s 22nd Annual Global Investment Conference on September 15, 2020, at 2:30 p.m. ET. The presentation will be available via a live webcast, and a replay will be accessible for 90 days afterwards on their website. Alzheimer’s affects approximately 5.8 million people in the U.S., and the number is expected to rise significantly, highlighting the increasing burden of this condition.
Details
News Market Reaction – SAVA
The recorded move for SAVA in the trading session of this news was +4.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present a corporate overview at H.C. Wainwright’s 22nd Annual Global Investment Conference.
| Event details follow: | |
| Date: | Tuesday, September 15th |
| Time: | 2:30 p.m. Eastern Time |
| Webcast: | https://www.CassavaSciences.com/company-presentations |
Cassava Sciences’ virtual public presentation can be followed live via webcast. It will also be available for replay for 90 days following the conference on CassavaSciences.com in the ‘Investors’ section.
About Alzheimer's Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. In the U.S. alone, approximately 5.8 million people are currently living with Alzheimer’s disease, and approximately 487,000 people age 65 or older developed Alzheimer’s in 2019.1 The number of people living with Alzheimer’s disease is expected to grow dramatically in the years ahead, resulting in a growing social and economic burden.2
About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third-party.
For More Information Contact:
Eric Schoen, Chief Financial Officer
Cassava Sciences, Inc.
eschoen@CassavaSciences.com
(512) 501-2450
1, 2 Source: Alzheimer’s Association. 2019 Alzheimer’s Disease Facts and Figures. Available online at: https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.